Australia markets open in 1 hour 46 minutes

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4300-0.1200 (-2.64%)
At close: 04:00PM EDT
4.5100 +0.08 (+1.81%)
After hours: 04:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.5500
Bid4.4200 x 200
Ask4.4500 x 400
Day's range4.4100 - 4.5942
52-week range3.2500 - 10.4500
Avg. volume1,291,366
Market cap374.962M
Beta (5Y monthly)0.66
PE ratio (TTM)N/A
EPS (TTM)-0.5000
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.50
  • Zacks

    Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?

    Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

    NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Of

  • Insider Monkey

    Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript

    Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript May 9, 2024 Anavex Life Sciences Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to the Anavex Life Sciences Fiscal 2024 Second Quarter Conference Call. […]